S&P 500   3,831.42 (+0.31%)
DOW   31,387.64 (+0.38%)
QQQ   310.46 (+0.42%)
AAPL   122.33 (+0.22%)
MSFT   231.10 (+1.56%)
FB   264.56 (+3.58%)
GOOGL   2,054.71 (+2.15%)
TSLA   643.88 (-1.43%)
AMZN   3,046.00 (+1.36%)
NVDA   507.14 (-0.99%)
BABA   233.96 (-0.98%)
CGC   31.61 (-4.90%)
GE   13.59 (+1.12%)
MU   86.78 (-2.61%)
NIO   40.54 (-2.38%)
AMD   80.17 (-0.85%)
T   28.96 (+0.84%)
F   12.13 (-0.33%)
ACB   10.00 (-4.40%)
DIS   189.82 (-1.27%)
BA   229.65 (+0.48%)
NFLX   527.15 (+1.24%)
PFE   34.80 (+1.19%)
S&P 500   3,831.42 (+0.31%)
DOW   31,387.64 (+0.38%)
QQQ   310.46 (+0.42%)
AAPL   122.33 (+0.22%)
MSFT   231.10 (+1.56%)
FB   264.56 (+3.58%)
GOOGL   2,054.71 (+2.15%)
TSLA   643.88 (-1.43%)
AMZN   3,046.00 (+1.36%)
NVDA   507.14 (-0.99%)
BABA   233.96 (-0.98%)
CGC   31.61 (-4.90%)
GE   13.59 (+1.12%)
MU   86.78 (-2.61%)
NIO   40.54 (-2.38%)
AMD   80.17 (-0.85%)
T   28.96 (+0.84%)
F   12.13 (-0.33%)
ACB   10.00 (-4.40%)
DIS   189.82 (-1.27%)
BA   229.65 (+0.48%)
NFLX   527.15 (+1.24%)
PFE   34.80 (+1.19%)
S&P 500   3,831.42 (+0.31%)
DOW   31,387.64 (+0.38%)
QQQ   310.46 (+0.42%)
AAPL   122.33 (+0.22%)
MSFT   231.10 (+1.56%)
FB   264.56 (+3.58%)
GOOGL   2,054.71 (+2.15%)
TSLA   643.88 (-1.43%)
AMZN   3,046.00 (+1.36%)
NVDA   507.14 (-0.99%)
BABA   233.96 (-0.98%)
CGC   31.61 (-4.90%)
GE   13.59 (+1.12%)
MU   86.78 (-2.61%)
NIO   40.54 (-2.38%)
AMD   80.17 (-0.85%)
T   28.96 (+0.84%)
F   12.13 (-0.33%)
ACB   10.00 (-4.40%)
DIS   189.82 (-1.27%)
BA   229.65 (+0.48%)
NFLX   527.15 (+1.24%)
PFE   34.80 (+1.19%)
S&P 500   3,831.42 (+0.31%)
DOW   31,387.64 (+0.38%)
QQQ   310.46 (+0.42%)
AAPL   122.33 (+0.22%)
MSFT   231.10 (+1.56%)
FB   264.56 (+3.58%)
GOOGL   2,054.71 (+2.15%)
TSLA   643.88 (-1.43%)
AMZN   3,046.00 (+1.36%)
NVDA   507.14 (-0.99%)
BABA   233.96 (-0.98%)
CGC   31.61 (-4.90%)
GE   13.59 (+1.12%)
MU   86.78 (-2.61%)
NIO   40.54 (-2.38%)
AMD   80.17 (-0.85%)
T   28.96 (+0.84%)
F   12.13 (-0.33%)
ACB   10.00 (-4.40%)
DIS   189.82 (-1.27%)
BA   229.65 (+0.48%)
NFLX   527.15 (+1.24%)
PFE   34.80 (+1.19%)
Log in
NASDAQ:AXSM

Axsome Therapeutics Competitors

$68.76
-1.42 (-2.02 %)
(As of 03/4/2021 11:27 AM ET)
Add
Compare
Today's Range
$68.22
Now: $68.76▼
$70.30
50-Day Range
$67.36
MA: $73.32▼
$80.44
52-Week Range
$35.44
Now: $68.76▼
$109.53
Volume10,156 shs
Average Volume293,829 shs
Market Capitalization$2.57 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.59

Competitors

Axsome Therapeutics (NASDAQ:AXSM) Vs. RDY, MRTX, BBIO, JAZZ, RARE, and ASND

Should you be buying AXSM stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Axsome Therapeutics, including Dr. Reddy's Laboratories (RDY), Mirati Therapeutics (MRTX), BridgeBio Pharma (BBIO), Jazz Pharmaceuticals (JAZZ), Ultragenyx Pharmaceutical (RARE), and Ascendis Pharma A/S (ASND).

Axsome Therapeutics vs. Dr. Reddy's Laboratories Stock

Dr. Reddy's Laboratories (NYSE:RDY) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Earnings & Valuation

This table compares Dr. Reddy's Laboratories and Axsome Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dr. Reddy's Laboratories$2.32 billion4.46$259 million$2.7922.28
Axsome TherapeuticsN/AN/A$-68,350,000.00($2.01)-34.21

Dr. Reddy's Laboratories has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

12.9% of Dr. Reddy's Laboratories shares are held by institutional investors. Comparatively, 63.6% of Axsome Therapeutics shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Comparatively, 26.0% of Axsome Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Dr. Reddy's Laboratories and Axsome Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Dr. Reddy's Laboratories8.23%16.33%10.79%
Axsome TherapeuticsN/A-62.33%-47.87%

Analyst Recommendations

This is a summary of current ratings and recommmendations for Dr. Reddy's Laboratories and Axsome Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Dr. Reddy's Laboratories00403.00
Axsome Therapeutics101102.83

Dr. Reddy's Laboratories presently has a consensus target price of $70.00, indicating a potential upside of 12.59%. Axsome Therapeutics has a consensus target price of $146.90, indicating a potential upside of 113.24%. Given Axsome Therapeutics' higher probable upside, analysts clearly believe Axsome Therapeutics is more favorable than Dr. Reddy's Laboratories.

Risk and Volatility

Dr. Reddy's Laboratories has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500. Comparatively, Axsome Therapeutics has a beta of 2.59, meaning that its stock price is 159% more volatile than the S&P 500.

Summary

Dr. Reddy's Laboratories beats Axsome Therapeutics on 8 of the 13 factors compared between the two stocks.

Axsome Therapeutics vs. Mirati Therapeutics Stock

Mirati Therapeutics (NASDAQ:MRTX) and Axsome Therapeutics (NASDAQ:AXSM) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Earnings & Valuation

This table compares Mirati Therapeutics and Axsome Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mirati Therapeutics$3.34 million2,823.68$-213,260,000.00($5.69)-32.73
Axsome TherapeuticsN/AN/A$-68,350,000.00($2.01)-34.21

Axsome Therapeutics has lower revenue, but higher earnings than Mirati Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Mirati Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

94.9% of Mirati Therapeutics shares are held by institutional investors. Comparatively, 63.6% of Axsome Therapeutics shares are held by institutional investors. 4.1% of Mirati Therapeutics shares are held by insiders. Comparatively, 26.0% of Axsome Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Mirati Therapeutics and Axsome Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mirati TherapeuticsN/A-60.01%-54.21%
Axsome TherapeuticsN/A-62.33%-47.87%

Analyst Recommendations

This is a summary of current ratings and recommmendations for Mirati Therapeutics and Axsome Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mirati Therapeutics151002.56
Axsome Therapeutics101102.83

Mirati Therapeutics presently has a consensus target price of $218.5714, indicating a potential upside of 17.20%. Axsome Therapeutics has a consensus target price of $146.90, indicating a potential upside of 113.24%. Given Axsome Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Axsome Therapeutics is more favorable than Mirati Therapeutics.

Risk and Volatility

Mirati Therapeutics has a beta of 1.64, meaning that its stock price is 64% more volatile than the S&P 500. Comparatively, Axsome Therapeutics has a beta of 2.59, meaning that its stock price is 159% more volatile than the S&P 500.

Summary

Axsome Therapeutics beats Mirati Therapeutics on 8 of the 12 factors compared between the two stocks.

Axsome Therapeutics vs. BridgeBio Pharma Stock

BridgeBio Pharma (NASDAQ:BBIO) and Axsome Therapeutics (NASDAQ:AXSM) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Earnings & Valuation

This table compares BridgeBio Pharma and Axsome Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BridgeBio Pharma$40.56 million230.74$-260,590,000.00($2.48)-25.33
Axsome TherapeuticsN/AN/A$-68,350,000.00($2.01)-34.21

Axsome Therapeutics has lower revenue, but higher earnings than BridgeBio Pharma. Axsome Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

95.5% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 63.6% of Axsome Therapeutics shares are held by institutional investors. 40.3% of BridgeBio Pharma shares are held by insiders. Comparatively, 26.0% of Axsome Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares BridgeBio Pharma and Axsome Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BridgeBio PharmaN/A-109.88%-48.54%
Axsome TherapeuticsN/A-62.33%-47.87%

Risk and Volatility

BridgeBio Pharma has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500. Comparatively, Axsome Therapeutics has a beta of 2.59, meaning that its stock price is 159% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for BridgeBio Pharma and Axsome Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BridgeBio Pharma01802.89
Axsome Therapeutics101102.83

BridgeBio Pharma presently has a consensus target price of $67.25, indicating a potential upside of 8.21%. Axsome Therapeutics has a consensus target price of $146.90, indicating a potential upside of 113.24%. Given Axsome Therapeutics' higher probable upside, analysts clearly believe Axsome Therapeutics is more favorable than BridgeBio Pharma.

Summary

Axsome Therapeutics beats BridgeBio Pharma on 7 of the 12 factors compared between the two stocks.

Axsome Therapeutics vs. Jazz Pharmaceuticals Stock

Axsome Therapeutics (NASDAQ:AXSM) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, risk, dividends, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations and price targets for Axsome Therapeutics and Jazz Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Axsome Therapeutics101102.83
Jazz Pharmaceuticals111602.83

Axsome Therapeutics currently has a consensus price target of $146.90, indicating a potential upside of 113.24%. Jazz Pharmaceuticals has a consensus price target of $184.00, indicating a potential upside of 14.18%. Given Axsome Therapeutics' higher probable upside, equities analysts plainly believe Axsome Therapeutics is more favorable than Jazz Pharmaceuticals.

Earnings & Valuation

This table compares Axsome Therapeutics and Jazz Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Axsome TherapeuticsN/AN/A$-68,350,000.00($2.01)-34.21
Jazz Pharmaceuticals$2.16 billion4.23$523.37 million$14.6011.13

Jazz Pharmaceuticals has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

63.6% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 95.7% of Jazz Pharmaceuticals shares are held by institutional investors. 26.0% of Axsome Therapeutics shares are held by insiders. Comparatively, 4.6% of Jazz Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Volatility & Risk

Axsome Therapeutics has a beta of 2.59, indicating that its share price is 159% more volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500.

Profitability

This table compares Axsome Therapeutics and Jazz Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Axsome TherapeuticsN/A-62.33%-47.87%
Jazz Pharmaceuticals7.86%20.16%10.85%

Summary

Jazz Pharmaceuticals beats Axsome Therapeutics on 9 of the 12 factors compared between the two stocks.

Axsome Therapeutics vs. Ultragenyx Pharmaceutical Stock

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Axsome Therapeutics (NASDAQ:AXSM) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.

Institutional and Insider Ownership

63.6% of Axsome Therapeutics shares are owned by institutional investors. 8.2% of Ultragenyx Pharmaceutical shares are owned by insiders. Comparatively, 26.0% of Axsome Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and target prices for Ultragenyx Pharmaceutical and Axsome Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ultragenyx Pharmaceutical06802.57
Axsome Therapeutics101102.83

Ultragenyx Pharmaceutical presently has a consensus price target of $131.20, indicating a potential upside of 7.82%. Axsome Therapeutics has a consensus price target of $146.90, indicating a potential upside of 113.24%. Given Axsome Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Axsome Therapeutics is more favorable than Ultragenyx Pharmaceutical.

Profitability

This table compares Ultragenyx Pharmaceutical and Axsome Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ultragenyx Pharmaceutical-119.19%-50.69%-26.87%
Axsome TherapeuticsN/A-62.33%-47.87%

Risk and Volatility

Ultragenyx Pharmaceutical has a beta of 2.19, indicating that its stock price is 119% more volatile than the S&P 500. Comparatively, Axsome Therapeutics has a beta of 2.59, indicating that its stock price is 159% more volatile than the S&P 500.

Earnings and Valuation

This table compares Ultragenyx Pharmaceutical and Axsome Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ultragenyx Pharmaceutical$103.71 million79.63$-402,730,000.00($7.36)-16.76
Axsome TherapeuticsN/AN/A$-68,350,000.00($2.01)-34.21

Axsome Therapeutics has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Summary

Axsome Therapeutics beats Ultragenyx Pharmaceutical on 10 of the 13 factors compared between the two stocks.

Axsome Therapeutics vs. Ascendis Pharma A/S Stock

Axsome Therapeutics (NASDAQ:AXSM) and Ascendis Pharma A/S (NASDAQ:ASND) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, earnings, dividends and analyst recommendations.

Profitability

This table compares Axsome Therapeutics and Ascendis Pharma A/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Axsome TherapeuticsN/A-62.33%-47.87%
Ascendis Pharma A/S-4,042.79%-55.72%-49.42%

Earnings and Valuation

This table compares Axsome Therapeutics and Ascendis Pharma A/S's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Axsome TherapeuticsN/AN/A$-68,350,000.00($2.01)-34.21
Ascendis Pharma A/S$14.98 million544.71$-244,180,000.00($5.25)-29.10

Axsome Therapeutics has higher earnings, but lower revenue than Ascendis Pharma A/S. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

63.6% of Axsome Therapeutics shares are owned by institutional investors. 26.0% of Axsome Therapeutics shares are owned by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Axsome Therapeutics and Ascendis Pharma A/S, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Axsome Therapeutics101102.83
Ascendis Pharma A/S001303.00

Axsome Therapeutics currently has a consensus target price of $146.90, indicating a potential upside of 113.24%. Ascendis Pharma A/S has a consensus target price of $183.00, indicating a potential upside of 20.28%. Given Axsome Therapeutics' higher possible upside, research analysts plainly believe Axsome Therapeutics is more favorable than Ascendis Pharma A/S.

Volatility & Risk

Axsome Therapeutics has a beta of 2.59, suggesting that its share price is 159% more volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500.

Summary

Axsome Therapeutics beats Ascendis Pharma A/S on 7 of the 13 factors compared between the two stocks.


Axsome Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.5$62.15-2.0%$10.13 billion$2.32 billion51.36
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.6$186.26-1.4%$9.56 billion$3.34 million-24.19Earnings Announcement
Analyst Report
Analyst Revision
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
1.6$62.83-1.7%$9.52 billion$40.56 million-18.43Analyst Report
Analyst Revision
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.1$162.47-0.3%$9.18 billion$2.16 billion51.25Analyst Report
Increase in Short Interest
Analyst Revision
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.2$123.36-1.6%$8.39 billion$103.71 million-28.10Analyst Report
Insider Selling
News Coverage
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.3$152.76-0.1%$8.17 billion$14.98 million-18.61
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.3$72.83-3.6%$7.83 billion$87.99 million-86.70
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.8$47.11-0.7%$7.59 billion$339.08 million-27.39Analyst Report
Analyst Revision
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.4$52.15-1.3%$7.44 billion$1.12 billion108.65Analyst Upgrade
Analyst Revision
United Therapeutics logo
UTHR
United Therapeutics
1.9$162.14-0.7%$7.27 billion$1.45 billion15.34Analyst Report
Analyst Revision
Schrödinger logo
SDGR
Schrödinger
1.5$78.08-27.0%$6.89 billion$85.54 million0.00Gap Up
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$86.31-0.9%$6.87 billion$380.83 million-11.04Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.5$215.01-0.1%$6.67 billion$311.33 million-125.01Decrease in Short Interest
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.9$35.54-2.3%$6.13 billionN/A0.00Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Allakos logo
ALLK
Allakos
1.7$111.56-0.2%$5.85 billionN/A-40.72Earnings Announcement
Insider Selling
Analyst Revision
News Coverage
AVIR
Atea Pharmaceuticals
1.7$65.01-8.6%$5.83 billionN/A0.00Upcoming Earnings
Decrease in Short Interest
Gap Up
Perrigo logo
PRGO
Perrigo
2.6$41.15-0.3%$5.63 billion$4.84 billion-685.72Earnings Announcement
Analyst Revision
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$42.80-0.2%$5.62 billion$150,000.00-20.19Earnings Announcement
Analyst Revision
News Coverage
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$91.39-1.8%$5.39 billion$66.51 million16.86
Galapagos logo
GLPG
Galapagos
1.3$86.01-4.3%$5.38 billion$1.00 billion-13.03Analyst Report
Gap Down
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.9$106.90-4.5%$5.38 billionN/A-30.46Earnings Announcement
Analyst Upgrade
Analyst Revision
News Coverage
Emergent BioSolutions logo
EBS
Emergent BioSolutions
1.8$93.01-1.8%$5.05 billion$1.11 billion29.91Analyst Upgrade
Eidos Therapeutics logo
EIDX
Eidos Therapeutics
1.0$122.21-0.0%$4.75 billion$26.69 million-46.12
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
1.8$80.02-1.0%$4.75 billionN/A-6.52Earnings Announcement
Analyst Report
Insider Buying
Analyst Revision
News Coverage
Gap Down
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.2$72.91-4.5%$4.45 billion$6.87 million-7.04Analyst Report
Analyst Revision
Gap Up
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$124.33-4.4%$4.43 billion$26.52 million-10.95Earnings Announcement
Analyst Revision
News Coverage
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.3$73.63-0.5%$4.42 billion$806.43 million-10.43Analyst Report
News Coverage
IMAB
I-Mab
1.1$56.81-7.8%$4.41 billion$4.31 million-1.97Analyst Report
News Coverage
Gap Up
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.30-2.4%$4.37 billion$204.89 million-36.63News Coverage
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$59.70-4.5%$4.32 billion$36.13 million-89.10Earnings Announcement
Analyst Report
Insider Selling
Decrease in Short Interest
Analyst Revision
News Coverage
Gap Up
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.3$22.19-5.6%$4.27 billion$114.62 million-8.95Earnings Announcement
Analyst Report
Analyst Revision
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$57.56-1.0%$4.01 billion$306.98 million-8.23Earnings Announcement
Analyst Revision
Gap Up
Insmed logo
INSM
Insmed
1.2$38.08-0.4%$3.91 billion$136.47 million-14.65Earnings Announcement
Analyst Report
Arvinas logo
ARVN
Arvinas
1.9$72.73-4.5%$3.68 billion$42.98 million-28.41Earnings Announcement
Analyst Downgrade
Insider Selling
Unusual Options Activity
Analyst Revision
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$45.79-0.6%$3.66 billionN/A-6.17Analyst Report
LEGN
Legend Biotech
1.2$25.52-1.1%$3.40 billion$64.39 million0.00Increase in Short Interest
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.6$119.11-2.1%$3.29 billionN/A-59.26Earnings Announcement
Analyst Report
Analyst Revision
MorphoSys logo
MOR
MorphoSys
0.4$24.77-0.1%$3.26 billion$80.43 million117.96News Coverage
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.5$45.77-0.7%$3.21 billion$117.91 million-9.28Analyst Downgrade
Analyst Revision
FibroGen logo
FGEN
FibroGen
1.6$34.60-0.7%$3.13 billion$256.58 million-13.26Earnings Announcement
Analyst Downgrade
Unusual Options Activity
Analyst Revision
ALX Oncology logo
ALXO
ALX Oncology
1.9$80.44-4.3%$3.11 billionN/A0.00Decrease in Short Interest
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.1$69.45-0.1%$3.01 billion$421.03 million24.45Analyst Report
News Coverage
Alkermes logo
ALKS
Alkermes
1.2$18.59-0.3%$2.97 billion$1.17 billion-40.41Analyst Revision
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.8$53.67-1.4%$2.92 billionN/A-29.49Earnings Announcement
Analyst Report
Analyst Revision
Gap Up
Viela Bio logo
VIE
Viela Bio
0.8$52.99-0.0%$2.91 billion$50 million-7.55Earnings Announcement
Decrease in Short Interest
Analyst Revision
OPKO Health logo
OPK
OPKO Health
1.9$4.27-1.2%$2.89 billion$901.90 million-23.72
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.6$24.51-0.4%$2.86 billion$306.49 million27.54
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$10.47-1.8%$2.78 billion$182.24 million-9.10Earnings Announcement
Analyst Report
Analyst Revision
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$71.58-0.1%$2.74 billion$644.77 million-10.21Increase in Short Interest
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$32.96-0.0%$2.67 billion$60,000.00-10.24
This page was last updated on 3/4/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.